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 We congratulate Arnold et al.  [1] for their interesting report 
on symmetrical drug-related intertriginous and flexural exanthe-
ma (SDRIFE, baboon syndrome). We especially commend the 
first criterion of this syndrome stating, what we emphasized some 
15 years ago  [2] , that SDRIFE should be distinguished from he-
matogenous or systemic contact-type dermatitis, as suggested by 
Andersen et al.  [3] , when they first reported this syndrome. 
 We would like to make two comments that by no means de-
tract from the scientific and educational value of this paper.
 First, the authors state that ‘the particular pattern of SDRIFE 
has not been observed so far’ as a reaction to radio contrast me-
dium (RCM). We refer them to our report  [4] describing 11 pa-
tients with SDRIFE, one of them (case 10) due to RCM, thus sup-
porting a causal relationship between RCM and SDRIFE.
 Second, the fifth criterion of SDRIFE is absence of systemic 
symptoms and signs, which according to the authors  [1] is impor-
tant to distinguish SDRIFE from drug rash with eosinophilia and 
systemic symptoms (DRESS). Here, we disagree. We contend that 
a patient with an eruption that has the cutaneous appearance of 
SDRIFE but with additional systemic organ involvement should 
still be classified as SDRIFE and not as DRESS. As we had sug-
gested in an earlier publication  [5] , we believe that all drug erup-
tions – involvement of other organ systems notwithstanding – are 
first and foremost dermatological diseases and, as such, they 
should be classified according to the cutaneous lesions. In other 
words, SDRIFE with systemic symptoms and/or eosinophilia 
should be defined as SDRIFE with systemic organ involvement 
and not as DRESS. 
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 We thank Dr. Wolf and Dr. Davidovici for their thoughtful 
comments on our case report  [1] .
 We regret that the clinical case observation of a 79-year-old 
woman who developed the particular pattern of flexural exan-
thema a few hours after receiving barium sulfate by the gastroin-
testinal route  [2] was not mentioned in our article. Since barium 
sulfate contains some additives, another allergen could have been 
responsible. To our best knowledge, iodinated radio contrast me-
dia have not been implicated in symmetrical drug-related inter-
triginous and flexural exanthema (SDRIFE) so far.
 We definitely agree with the authors that the description and 
diagnosis of cutaneous drug eruptions often require the expertise 
of a dermatologist. However, most patients with cutaneous drug 
eruptions are initially seen by nondermatologists such as general 
practitioners. Particularly these physicians should be aware of the 
specific danger signs of the severer drug eruptions with internal 
organ involvement  [3] . On the other hand, we believe that it is less 
a particular morphological pattern, such as a maculopapular ex-
anthema or SDRIFE, than the danger signs of severer reactions, 
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such as high fever, general malaise, eosinophilia or hepatic in-
volvement, which should alert the treating physicians to suspect 
a severe drug reaction and to seek advice of a specialist.
 Neither in the literature nor in our many personal observa-
tions of patients with SDRIFE have we been able to identify cases, 
who also suffered from severe systemic symptoms or signs, such 
as high fever, cytopenia, eosinophilia or hepatitis. Also e.g. drug 
rash with eosinophilia and systemic symptoms is typically associ-
ated with maculopapular lesions, which are an integral part of the 
complete syndrome, and toxic epidermal necrolysis often begins 
with a primarily innocuous macular sometimes painful exanthe-
ma  [4] . This implies that independently of the type of cutaneous 
manifestation, the presence of alert signs should always be 
searched for and respected.
 If in the future cases with the particular morphological pat-
tern of SDRIFE and severe systemic signs should be published, a 
reevaluation of our currently proposed criteria might be neces-
sary. Currently, however, we hypothesize that SDRIFE belongs to 
the clinically heterogenous group of T-cell-mediated macular, 
maculopapular, papular and pustular exanthemas which may be 
associated with mild systemic symptoms, such as mild fever or 
pruritus, but it is not associated with an involvement of internal 
organs. The reason for the particular distribution of the exan-
thema remains to be elucidated. 
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